tuneTypical Dose
2–3 g/day
Amino Acid
L-Carnitine
L-Carnitine
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
weeks to months, context-dependent
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
L-carnitine transports long-chain fatty acids into mitochondria for energy production. It is used for fatigue reduction, recovery support, and male fertility-related outcomes, especially in low-status groups.
The better-supported carnitine uses are still fairly targeted: selected male-factor infertility protocols, fatigue in frail older adults, and modest metabolic or body-composition effects in some high-risk populations. A newer network meta-analysis keeps carnitine-containing fertility regimens credible, but the evidence still clusters around combination formulas rather than clean monotherapy proof. That means L-carnitine should stay in the targeted mitochondrial-support lane, not in generic fat-burner marketing.
L-Carnitine supports mitochondrial fatty-acid transport and may affect acylcarnitine handling. Human outcomes are population-specific and inconsistent outside targeted clinical contexts.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Motile sperm outcomes improved in one controlled male infertility RCT. Short-term fatigue and function improvements reported in centenarian RCT.
Secondary Outcomes
- No acute CrossFit performance benefit in one RCT. Possible short-term DOMS/CK/LDH benefit in pooled exercise-recovery studies.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- Active seizure disorder
- Severe kidney disease
Side effects
- Nausea
- Stomach upset
- Fishy body odor
- Diarrhea
Interactions
- Anticonvulsants
- Renal-risk medications
- Unknown stimulant stacking
Avoid if
- Active severe renal disease
- Active unstable psychiatric/cardiac status
- Poor pregnancy/lactation risk management
Evidence
Study-level References
l-carnitine-SRC-001Randomized controlled trial (multigroup comparator)
Sourceopen_in_newPMID: 16281510 (no DOI listed)
Population: 150 men with oligoasthenozoospermia
Dose protocol: L-carnitine 2 g/day + ALCAR 1 g/day, orally, twice daily for 3 months.
Key findings: Directional benefit. Forward/total motile sperm improved and pregnancy rate approximately tripled in treated arm. In a 3-month trial, treated arm had higher forward and total motile sperm and higher pregnancy proportion than control.
Notes: Non-placebo control group with language/region constraints and incomplete replication context.
Paper content
moderate-positive; forward/total motile sperm improved significantly, pregnancy rate higher than control Significant increase in motile parameters and higher pregnancy proportion; forward motile/total motile improvements reached significance, while some secondary counts were mixed.
l-carnitine-SRC-002Randomized, double-blind, placebo-controlled
Sourceopen_in_newMalaguarna et al. _Am J Clin Nutr_. 2007;86(5):1738-1744. PMID: 18065594.
Population: 66 centenarians with fatigue after minor activity.
Dose protocol: 2 g/day levocarnitine for 3 months, placebo-controlled, double-blind.
Key findings: Physical and mental fatigue, MMSE, and some body-composition outcomes improved vs placebo in this cohort. Improvements in physical fatigue scores and cognitive/functional indices were significant in one small, specific elderly cohort.
Notes: Highly specific population and age cohort. Limited external generalizability.
Paper content
Reduced fat/muscle decline metrics and improved fatigue and MMSE-like outcomes versus placebo.
l-carnitine-SRC-003Randomized double-blind placebo-controlled crossover
Sourceopen_in_newPMID: 40944177, DOI: 10.3390/nu17172784
Population: 20 trained male recreational CrossFit participants.
Dose protocol: 3 g L-carnitine tartrate acutely before the workout, crossover with placebo.
Key findings: Null effect on performance. Repetitions (≈202.4 vs 204.5, p = 0.810). No meaningful enhancement in CrossFit performance. No RPE or BP differences. Some transient sleep difficulty.
Notes: Small sample and acute design. Results limited to one workout format.
Paper content
Null effect on performance; repetitions (≈202.4 vs 204.5; p = 0.810). No meaningful enhancement in CrossFit performance; no RPE or BP differences; some transient sleep difficulty.
l-carnitine-SRC-004Systematic review and meta-analysis
Sourceopen_in_newYarizadh et al. _J Am Coll Nutr_. 2020;39(5):457-468. PMID: 32154768.
Population: 7 RCTs on exercise-induced muscle damage.
Dose protocol: Variable oral L-carnitine regimens from pooled trials.
Key findings: Small short-term improvements in DOMS and some damage markers. Durability beyond early post-exercise windows was not sustained. Suggests possible early soreness/marker benefits, with high study heterogeneity.
Notes: Substantial heterogeneity, protocol variation, and short follow-up windows reduce confidence for routine use.
Paper content
Reductions in soreness and early CK/MB/LDH signals at acute timepoints.
l-carnitine-SRC-005Meta-analysis of randomized controlled trials
Sourceopen_in_newPMID: 31481697, DOI: 10.1038/s41371-019-0248-1
Population: 10 eligible RCTs, adults (n = 1,412).
Dose protocol: Oral L-carnitine with varying doses. Subgroup effects stronger at <2 g/day and in overweight/obese cohorts for DBP.
Key findings: No meaningful SBP change. Small DBP reduction (~−1.16 mmHg pooled). Supports minor BP effect size. Uncertain clinical significance at individual level.
Notes: Moderate pooled effect size with notable between-study heterogeneity. Mechanism not fully established.
Paper content
No meaningful SBP change; small DBP reduction (~−1.16 mmHg pooled). Supports minor BP effect size, uncertain clinical significance at individual level.
l-carnitine-SRC-006Systematic review and meta-analysis of 37 RCTs.
Sourceopen_in_newTalenezhad N, Mohammadi M, Ramezani-Jolfaie N, Mozaffari-Khosravi H, Salehi-Abargouei A. Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. Clin Nutr ESPEN. 2020;37:9-23. doi:10.1016/j.clnesp.2020.03.008. PMID:32359762.
Population: Adults from 37 RCTs with varying health conditions.
Dose protocol: Oral L-carnitine at varying doses across 37 RCTs (2,292 participants). Optimal effects at approximately 2 g/day.
Key findings: Body weight reduced by 1.21 kg, BMI by 0.24 kg/m2, fat mass by 2.08 kg. No significant change in waist circumference or body fat percentage.
Notes: Meta-analysis of 37 RCTs. Effects modest but consistent. Stronger signals in overweight and obese populations.
Paper content
This meta-analysis pooled 37 RCTs (2,292 participants) to assess L-carnitine supplementation effects on body composition. L-carnitine significantly reduced body weight by 1.21 kg, BMI by 0.24 kg/m2, and fat mass by 2.08 kg. No significant changes were found for waist circumference or body fat percentage. Dose-response analysis indicated optimal effects at approximately 2,000 mg/day. Subgroup analyses favored overweight and obese populations. The effect sizes are modest but consistent across a large number of pooled trials.
l-carnitine-SRC-007Systematic review and dose-response meta-analysis of 21 RCTs.
Sourceopen_in_newMirrafiei A, Jayedi A, Shab-Bidar S. The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Clin Ther. 2024;46(5):404-410. doi:10.1016/j.clinthera.2024.03.002. PMID:38594107.
Population: Adults with type 2 diabetes across 21 RCTs.
Dose protocol: L-carnitine at varying doses in 21 RCTs (2,041 T2DM patients). U-shaped BMI response peaking at 2 g/day.
Key findings: Modest improvements in BMI, glycemic control, and lipid profiles in T2DM patients. Substantial heterogeneity limits confidence.
Notes: T2DM-specific dose-response meta-analysis. Results should be interpreted cautiously due to heterogeneity.
Paper content
This dose-response meta-analysis pooled 21 RCTs (2,041 patients with T2DM) evaluating L-carnitine supplementation. Results showed that every 1 g/day increment of L-carnitine significantly reduced BMI, with a U-shaped effect peaking at 2 g/day. Modest improvements in glycemic and lipid parameters were observed. The authors cautioned that substantial statistical heterogeneity limits confidence, and results should be interpreted carefully. The study provides the most focused meta-analytic evidence for L-carnitine in the T2DM population specifically.
l-carnitine-SRC-008Systematic review and network meta-analysis
Sourceopen_in_newZafar MI, Mills KE, Baird CD, Jiang H, Li H, et al. Effectiveness of Nutritional Therapies in Male Factor Infertility Treatment: A Systematic Review and Network Meta-analysis. Drugs. 2023;83(7):635-649. doi:10.1007/s40265-023-01853-0. PMID:36943634.
Population: Adult men with infertility or subfertility enrolled in nutritional-therapy studies.
Dose protocol: Systematic review and network meta-analysis of nutritional therapies for male infertility with mixed regimens and durations.
Key findings: Carnitine-containing regimens ranked among the more credible nutritional options for motility-related fertility outcomes.
Notes: Useful as a modernization source because it reduces reliance on a single old fertility trial, but formula heterogeneity still limits monotherapy certainty.
Paper content
This network meta-analysis modernizes the old single-trial carnitine fertility framing. It suggests that carnitine-containing regimens remain among the more credible nutritional options for motility-related outcomes, but the evidence is still heterogeneous and spread across mixed formulas rather than clean monotherapy proof.